Rigaku Sponsors Carl Brändén Award
News Jun 04, 2007
Rigaku Corporation announced its annual sponsorship of the Carl Brändén Award at the 7th European Symposium of The Protein Society on May 12, 2007 in Stockholm, Sweden.
In presenting the first award, Rigaku Chairman and CEO Mr. Hikaru Shimura said, "In the tradition of the late Carl Brändén, a pioneer in structural biology ... the Carl Brändén Award, sponsored by Rigaku Corporation, will be awarded annually to an outstanding protein scientist who has also made exceptional contributions in the areas of education and/or service to protein science."
Mr. Shimura continued that, "Carl Brändén was a pioneer in the use of X-ray crystallography to study the structure of proteins and tirelessly promoted the field since the early 1960s. Rigaku’s interest in structural biology follows in the footsteps of pioneers such as Carl Brändén."
The 2007 Carl Brändén Award was presented to Prof. Lubert Stryer (Professor Emeritus at the Stanford University School of Medicine) by Mr. Shimura. Dr. Stryer received the award for his exceptional contributions to education in biochemistry and molecular biology.
In addition to his pioneering science on the measurement of distances in proteins and on the biochemistry of vision, Dr. Stryer wrote four editions of Biochemistry, the textbook which has educated more than two generations students and scientists around the world.
The Protein Society is an international society devoted to furthering research and development in protein science.
A nonprofit scientific and educational organization founded in 1986, to consolidate the knowledge and experience of a global community of protein scientists and to explore all aspects of the building blocks of life, The Protein Society is a member of the Federation of American Societies for Experimental Biology (FASEB), which represents a coalition of 21 independent societies that play an active role in lobbying for the interests of biomedical scientists.
The purpose of the Society is to provide national and international forums to facilitate communication, cooperation and collaboration with respect to all aspects of the study of proteins.
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE